EGFR and non-small cell lung carcinoma: A third-generation EGFR TKI, osimertinib, overcame this resistance mechanism resulting in superior efficacy and garnered FDA approval in 2018 as a first-line NSCLC treatment option, regardless of T790M mutational status 8, 9.